ArticleJournal of virology2017
Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication
Open access · bronzeAbstract read
In one paragraph
Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 43 citations in OpenAlex.
- Two or Three? Clinical and Proteomic Perspectives on Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV Treatment.Open forum infectious diseases · 2025Trial
- Persistent viral control status is associated with enhanced innate immune responses in people with HIV-1.iScience · 2026Article
- microRNA-422a promotes HIV replication and innate immune evasion by targeting MECP2.Molecular therapy. Nucleic acids · 2026Article
- Unsupervised proteomic stratification of people living with HIV reveals inflammatory biotypes beyond conventional clinical classifications.Frontiers in immunology · 2026Article
- Macrophage-Derived Factors with the Potential to Contribute to the Pathogenicity of HIV-1 and HIV-2: Roles of M-CSF and CXCL7.International journal of molecular sciences · 2025Article
- Vitamin D Decreases Susceptibility of CD4Biomolecules · 2025Article
- Transposable elements may enhance antiviral resistance in HIV-1 elite controllers.Genome biology · 2025Article
- The multifaceted role of XCL1 in health and disease.Protein science : a publication of the Protein Society · 2025Review
- Natural Resistance to HIV Infection: Role of Immune Activation.Immunity, inflammation and disease · 2025Review
- HIV controllers: hope for a functional cure.Frontiers in immunology · 2025Review
- Article
- Transposable elements may enhance antiviral resistance in HIV-1 elite controllers.bioRxiv : the preprint server for biology · 2023Article
- CCR5∆32 and SDF1 3'A: Gene Variants, Expression and Influence on Biological Markers for the Clinical Progression to AIDS among HIV-1 Virus Controllers in a Mixed Population of the Amazon Region of Brazil.International journal of molecular sciences · 2023Article
- T-Follicular-Like CD8Frontiers in immunology · 2022Article
- Infectious bursal disease virus replication is inhibited by avain T cell chemoattractant chemokine CCL19.Frontiers in microbiology · 2022Article
- Reversal of the CD8Frontiers in immunology · 2021Article
- A Novel Sample Selection Approach to Aid the Identification of Factors That Correlate With the Control of HIV-1 Infection.Frontiers in immunology · 2021Article
- Platelets in HIV: A Guardian of Host Defence or Transient Reservoir of the Virus?Frontiers in immunology · 2021Review
- Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection.Breast cancer research : BCR · 2020Observational
- Discovery of Potential Chemical Probe as Inhibitors of CXCL12 Using Ligand-Based Virtual Screening and Molecular Dynamic Simulation.Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 8 institutions in 1 country.
Evan S JacobsBlood Systems Research Institute, San Francisco, California, USA.
Sheila M KeatingBlood Systems Research Institute, San Francisco, California, USA skeating@bloodsystems.org pnorris@bloodsystems.org.
Mohamed Abdel-MohsenBlood Systems Research Institute, San Francisco, California, USA.
Stuart L GibbBlood Systems Research Institute, San Francisco, California, USA.
John W HeitmanBlood Systems Research Institute, San Francisco, California, USA.
Heather C InglisBlood Systems Research Institute, San Francisco, California, USA.
Jeffrey N MartinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Jinbing ZhangJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Zhanna KaidarovaBlood Systems Research Institute, San Francisco, California, USA.
Xutao DengBlood Systems Research Institute, San Francisco, California, USA.
Shiquan WuBlood Systems Research Institute, San Francisco, California, USA.
Kathryn AnastosAlbert Einstein College of Medicine, Bronx, New York, USA.
Howard CrystalSUNY Downstate Medical Center, Brooklyn, New York, USA.
Maria C VillacresKeck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Mary YoungGeorgetown University Medical Center, Washington, DC, USA.
Ruth M GreenblattDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Alan L LandayRush University Medical Center, Chicago, Illinois, USA.
Stephen J GangeJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Steven G DeeksDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Elizabeth T GolubJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Satish K PillaiBlood Systems Research Institute, San Francisco, California, USA.
Philip J NorrisBlood Systems Research Institute, San Francisco, California, USA skeating@bloodsystems.org pnorris@bloodsystems.org.ORCID http://orcid.org/0000-0003-0526-2088
Blood Systems Research Institute · USUniversity of California, San Francisco · USJohns Hopkins University · USAlbert Einstein College of Medicine · USGeorgetown University · USRush University Medical Center · USSUNY Downstate Health Sciences University · USUniversity of Southern California · US
Funding
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6MEffects of Cell-Intrinsic Immunity on Establishment and Reversal of HIV LatencyR01GM117901 · NIGMS · VITALANT · PI PILLAI, SATISH KUMAR · 2015 to 2018
$1.5MEffects of Cell-Intrinsic Immunity on Establishment and Reversal of HIV LatencyR01AI150449 · NIAID · VITALANT · PI PILLAI, SATISH KUMAR · 2019 to 2019
$305kNIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI150449NIGMS NIH HHS R01 GM117901
Abstract
A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4
Indexed as
AdultAntigens, DifferentiationCD4-Positive T-LymphocytesCytokinesFemaleGene Expression RegulationHIVHIV InfectionsHIV Long-Term SurvivorsHumansMembrane ProteinsMiddle AgedPlasmaReceptors, HIVVirus ReplicationAntigens, DifferentiationCytokinesIFITM2 protein, humanleu-13 antigenMembrane ProteinsReceptors, HIVchemokine receptorscytokineselite controlHIVrestriction factor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.